My ePortfolio Register   

AACR 2017 /
Redefining tamoxifen for breast cancer

1st - 5th Apr 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.17
Views: 833

Gokul Das - Roswell Park Cancer Institute, Buffalo, USA

Dr Das speaks with ecancer at AACR 2017 about the effect of tamoxifen before surgery on the genome of breast cancer cells.

He reports that binding of oestrogen receptors deactivates p53, a tumour suppressor gene, based on sequencing after four weeks of tamoxifen therapy.

Dr Das describes these findings pointing towards p53 activation as a predictor of tamoxifen response, with further trials to confirm utility in stratifying patients with triple negative breast cancer.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence